465PA phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours

ConclusionsThrough all doses tested thus far, VT1021 has been shown to be safe for patients and induces expression of Tsp-1.Clinical trial identificationNCT03364400 December 6, 2017.Legal entity responsible for the studyVigeo Therapeutics, Inc.FundingVigeo Therapeutics, Inc.DisclosureS. Wang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Vigeo Therapeutics, Inc. K. Kerstein: Full / Part-time employment: Vigeo Therapeutics, Inc. G. Berk: Advisory / Consultancy: Vigeo Therapeutics, Inc. M.J. Cieslewicz: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Vigeo Therapeutics. J. Watnick: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Vigeo Therapeutics, Inc. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research